Want to see HK:6622 full AI Analyst Report?
Top Page
Zhaoke Ophthalmology Ltd.
(6622)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$2.50
▼(-21.14% Downside)
Action:Reiterated
Date:04/28/26
The score is primarily held back by persistent losses, unstable revenue trends, negative gross profit in 2025, and ongoing cash burn, which together imply continued funding and execution risk. Technical indicators add a modest headwind with the stock trading below key longer-term moving averages and weak momentum. A relatively moderate leverage profile and sizeable equity provide some support, but not enough to offset the operating and cash flow weakness.
Positive Factors
Focused ophthalmology franchise
A dedicated ophthalmology focus creates a durable specialization: concentrated R&D expertise, deeper clinical/regulatory know-how, and a clearer commercial go-to-market for eye therapies. In‑licensing plus internal development broadens the product funnel and reduces sole dependence on single candidates.
Negative Factors
Persistent operating losses
Sustained operating losses indicate the business has not yet demonstrated a scalable, profitable model. Continued deficits will erode equity, force recurring financing, and constrain reinvestment in R&D or commercialization, raising structural execution and dilution risks over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused ophthalmology franchise
A dedicated ophthalmology focus creates a durable specialization: concentrated R&D expertise, deeper clinical/regulatory know-how, and a clearer commercial go-to-market for eye therapies. In‑licensing plus internal development broadens the product funnel and reduces sole dependence on single candidates.
Read all positive factors
Zhaoke Ophthalmology Ltd. (6622) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.42B
Dividend YieldN/A
Average Volume (3M)1.25M
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue Growth-53.85%
EPS Growth12.23%
CountryHK
Employees294
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding548,749,000
10 Day Avg. Volume1,172,850
30 Day Avg. Volume1,251,992
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)0.92
Price to Sales (P/S)46.69
P/FCF Ratio-5.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)HK$421.50M
Zhaoke Ophthalmology Ltd. Business Overview & Revenue Model
Company Description
Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company i...
How the Company Makes Money
null...
Zhaoke Ophthalmology Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.15M | 69.32M | 18.75M | 0.00 | 0.00 |
| Gross Profit | -32.57M | 51.80M | 14.25M | 0.00 | 0.00 |
| EBITDA | -215.45M | -251.23M | -327.86M | -384.55M | -377.53M |
| Net Income | -203.57M | -237.49M | -385.04M | -407.32M | -2.13B |
Balance Sheet | |||||
| Total Assets | 1.94B | 2.24B | 2.42B | 2.57B | 2.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.30B | 1.19B | 1.46B | 1.73B | 2.14B |
| Total Debt | 292.48M | 238.59M | 238.03M | 131.93M | 37.03M |
| Total Liabilities | 359.58M | 343.44M | 372.02M | 222.25M | 109.92M |
| Stockholders Equity | 1.58B | 1.90B | 2.05B | 2.35B | 2.50B |
Cash Flow | |||||
| Free Cash Flow | -265.04M | -297.79M | -418.93M | -569.60M | -339.63M |
| Operating Cash Flow | -260.20M | -253.72M | -323.66M | -331.05M | -245.14M |
| Investing Cash Flow | 109.11M | -116.45M | -75.77M | -324.57M | 683.52M |
| Financing Cash Flow | 45.63M | -12.12M | 99.29M | 76.23M | 1.66B |
Zhaoke Ophthalmology Ltd. Technical Analysis
Negative
3.17
Price Trends
2.73
Negative
2.98
Negative
3.17
Negative
Market Momentum
-0.05
Positive
47.50
Neutral
38.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6622, the sentiment is Negative. The current price of 3.17 is above the 20-day moving average (MA) of 2.60, above the 50-day MA of 2.73, and below the 200-day MA of 3.17, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 47.50 is Neutral, neither overbought nor oversold. The STOCH value of 38.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6622.
Zhaoke Ophthalmology Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
HK:6622
Zhaoke Ophthalmology Ltd.
2.61
0.09
3.57%
HK:1477
Ocumension Therapeutics
5.09
-4.00
-44.00%
Zhaoke Ophthalmology Ltd. Corporate Events
Zhaoke Ophthalmology’s Myopia Drug NVK002 Accepted for Australian TGA Evaluation
Jun 15, 2026
Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration has accepted for evaluation its registration application for Atropine Sulfate Eye Drops (0.02% strength), known as NVK002, intended to slow myopia progr...
Zhaoke Ophthalmology Launches HK$100 Million Share Buy-Back Plan
Jun 8, 2026
Zhaoke Ophthalmology has approved a 12-month on-market share repurchase plan of up to HK$100 million, allowing it to buy back up to 10% of its issued shares under an existing shareholder mandate. The repurchased shares will be cancelled, and the c...
Zhaoke Ophthalmology Strikes Indonesia Distribution Deal for Dry Eye Gel
Jun 5, 2026
Zhaoke Ophthalmology has signed an exclusive distribution and supply agreement with Indonesian drug maker PT Erlangga Edi Laboratories to commercialize its CsA Ophthalmic Gel for moderate-to-severe dry eye disease in Indonesia. Under the deal, PT ...
Zhaoke Ophthalmology Shareholders Approve All Resolutions at 2026 AGM
May 15, 2026
Zhaoke Ophthalmology Limited reported that all resolutions proposed at its annual general meeting held on May 15, 2026 were approved by shareholders by way of poll. Investors granted the board mandates to repurchase up to 10% of issued shares, iss...
Zhaoke Ophthalmology Renews Related-Party CMO Deal for Eyprotor
Apr 30, 2026
Zhaoke Ophthalmology has renewed its contract manufacturing arrangement with related party Lee’s Pharm Hefei to secure continued production of its ophthalmic drug Eyprotor for commercial sale. The deal is structured through a supplemental ag...
Zhaoke Ophthalmology Sets 2026 AGM to Seek Share Repurchase and Issuance Mandates
Apr 23, 2026
Zhaoke Ophthalmology Limited has called its annual general meeting for May 15, 2026, in Hong Kong, where shareholders will vote on key share capital mandates. The agenda includes proposals to authorize the board to repurchase up to 10% of the comp...
Zhaoke Ophthalmology Moves to Update Articles for Hybrid Meetings and New HK Rules
Apr 15, 2026
Zhaoke Ophthalmology Limited plans to overhaul its articles of association, replacing the existing version with amended and restated articles to align with updated Hong Kong listing and regulatory standards. The move focuses on facilitating hybrid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.